Ardelyx, Inc. (ARDX)
3.08
-0.12
(-3.75%)
USD |
NASDAQ |
Oct 23, 16:00
3.065
-0.02
(-0.49%)
Pre-Market: 20:00
Ardelyx Enterprise Value : 741.73M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 741.73M |
| October 22, 2026 | 771.63M |
| October 21, 2026 | 754.19M |
| October 20, 2026 | 774.12M |
| October 19, 2026 | 744.22M |
| October 16, 2026 | 744.22M |
| October 15, 2026 | 789.07M |
| October 14, 2026 | 769.14M |
| October 13, 2026 | 751.70M |
| October 12, 2026 | 779.11M |
| October 09, 2026 | 791.56M |
| October 08, 2026 | 789.07M |
| October 07, 2026 | 786.58M |
| October 06, 2026 | 799.04M |
| October 05, 2026 | 818.97M |
| October 02, 2026 | 806.51M |
| October 01, 2026 | 816.48M |
| September 30, 2026 | 826.44M |
| September 29, 2026 | 818.97M |
| September 28, 2026 | 823.95M |
| September 25, 2026 | 826.44M |
| September 24, 2026 | 833.92M |
| September 23, 2026 | 841.39M |
| September 22, 2026 | 876.27M |
| September 21, 2026 | 846.37M |
| Date | Value |
|---|---|
| September 18, 2026 | 826.44M |
| September 17, 2026 | 816.48M |
| September 16, 2026 | 818.97M |
| September 15, 2026 | 821.46M |
| September 14, 2026 | 851.36M |
| September 11, 2026 | 866.31M |
| September 10, 2026 | 876.27M |
| September 09, 2026 | 921.12M |
| September 08, 2026 | 913.64M |
| September 04, 2026 | 916.14M |
| September 03, 2026 | 898.70M |
| September 02, 2026 | 921.12M |
| September 01, 2026 | 911.15M |
| August 31, 2026 | 916.14M |
| August 28, 2026 | 923.61M |
| August 27, 2026 | 926.10M |
| August 26, 2026 | 928.59M |
| August 25, 2026 | 916.14M |
| August 24, 2026 | 906.17M |
| August 21, 2026 | 943.54M |
| August 20, 2026 | 946.03M |
| August 19, 2026 | 978.42M |
| August 18, 2026 | 951.02M |
| August 17, 2026 | 985.90M |
| August 14, 2026 | 985.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Capricor Therapeutics, Inc. | 197.70M |
| Compass Therapeutics, Inc. | -33.20M |
| ARS Pharmaceuticals, Inc. | 353.57M |
| Sionna Therapeutics, Inc. | -40.37M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.72M |
| Revenue (Quarterly) | 120.88M |
| Total Expenses (Quarterly) | 137.60M |
| EPS Diluted (Quarterly) | -0.0674 |
| Gross Profit Margin (Quarterly) | 94.74% |
| Profit Margin (Quarterly) | -13.83% |
| Earnings Yield | -7.34% |
| Normalized Earnings Yield | -7.338 |